Pub Date : 2024-10-01Epub Date: 2024-08-02DOI: 10.1111/all.16253
Stephanie A Kubala, Fernanda D Young, Viviane Callier, Marjohn M Rasooly, Caeden Dempsey, Erica Brittain, Pamela A Frischmeyer-Guerrerio
Background: While food allergy (FA) can be fatal, the greatest public health impact of FA arguably lies in its detrimental effect on quality of life (FAQOL). Understanding the factors that contribute to FAQOL at different ages is essential to develop personalized interventions that will improve FAQOL.
Objective: To determine the most influential factors that impact FAQOL across ages in well-phenotyped participants with confirmed FA.
Methods: One hundred and twenty-five individuals aged 2-28 years with IgE-mediated FA completed validated age-specific FAQOL questionnaires. The relationship between demographic/clinical variables and scores were analyzed to identify key predictors of FAQOL.
Results: Poor FAQOL was associated with increasing age, strict avoidance practices, reactions to trace exposures, and more severe reactions as assessed by epinephrine use, anaphylaxis, and/or treatment in the emergency department; FAQOL improved with time from the event. FAQOL was worse in subjects avoiding >2 versus ≤2 foods and in those avoiding milk, egg, soy, sesame, or wheat. Number of foods avoided had greatest impact on children ages 2-7 years, while total number of allergic reactions strongly impacted FAQOL in teens and adults; FAQOL of subjects ages 8-12 years appeared less affected by these variables compared to other age groups. A decision tree analysis identified key predictors of overall FAQOL (age, number of food avoidances, and time since epinephrine use) that can be used to guide intervention strategies to improve FAQOL.
Conclusion: We directly compared FAQOL in extensively phenotyped children, teenagers, and adults with confirmed IgE-mediated FA. Age; timing, number, and severity of reactions; type and number of FA; and food avoidance practices influence FAQOL and should guide intervention strategies.
{"title":"Key factors that influence quality of life in patients with IgE-mediated food allergy vary by age.","authors":"Stephanie A Kubala, Fernanda D Young, Viviane Callier, Marjohn M Rasooly, Caeden Dempsey, Erica Brittain, Pamela A Frischmeyer-Guerrerio","doi":"10.1111/all.16253","DOIUrl":"10.1111/all.16253","url":null,"abstract":"<p><strong>Background: </strong>While food allergy (FA) can be fatal, the greatest public health impact of FA arguably lies in its detrimental effect on quality of life (FAQOL). Understanding the factors that contribute to FAQOL at different ages is essential to develop personalized interventions that will improve FAQOL.</p><p><strong>Objective: </strong>To determine the most influential factors that impact FAQOL across ages in well-phenotyped participants with confirmed FA.</p><p><strong>Methods: </strong>One hundred and twenty-five individuals aged 2-28 years with IgE-mediated FA completed validated age-specific FAQOL questionnaires. The relationship between demographic/clinical variables and scores were analyzed to identify key predictors of FAQOL.</p><p><strong>Results: </strong>Poor FAQOL was associated with increasing age, strict avoidance practices, reactions to trace exposures, and more severe reactions as assessed by epinephrine use, anaphylaxis, and/or treatment in the emergency department; FAQOL improved with time from the event. FAQOL was worse in subjects avoiding >2 versus ≤2 foods and in those avoiding milk, egg, soy, sesame, or wheat. Number of foods avoided had greatest impact on children ages 2-7 years, while total number of allergic reactions strongly impacted FAQOL in teens and adults; FAQOL of subjects ages 8-12 years appeared less affected by these variables compared to other age groups. A decision tree analysis identified key predictors of overall FAQOL (age, number of food avoidances, and time since epinephrine use) that can be used to guide intervention strategies to improve FAQOL.</p><p><strong>Conclusion: </strong>We directly compared FAQOL in extensively phenotyped children, teenagers, and adults with confirmed IgE-mediated FA. Age; timing, number, and severity of reactions; type and number of FA; and food avoidance practices influence FAQOL and should guide intervention strategies.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-07-22DOI: 10.1111/all.16237
T C Timothy Chin-See-Chong, J P M Johanna van der Valk, J A Janice Layhadi, M H Mohamed Shamji, J H Jasper Kappen
{"title":"Clinical efficacy of tezepelumab in pre-selected non-type 2 asthma patients.","authors":"T C Timothy Chin-See-Chong, J P M Johanna van der Valk, J A Janice Layhadi, M H Mohamed Shamji, J H Jasper Kappen","doi":"10.1111/all.16237","DOIUrl":"10.1111/all.16237","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141732938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-07-20DOI: 10.1111/all.16249
Kirsten E Stewart, Chris RuiWen Kuo, Rory Chan, Brian J Lipworth
{"title":"Effects of dupilumab on quality of life burden in refractory type 2 high unified airway disease.","authors":"Kirsten E Stewart, Chris RuiWen Kuo, Rory Chan, Brian J Lipworth","doi":"10.1111/all.16249","DOIUrl":"10.1111/all.16249","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141732939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-07-14DOI: 10.1111/all.16225
Tali Czarnowicki, Eden David, Kazuhiko Yamamura, Joseph Han, Helen He, Ana B Pavel, Jacob Glickman, Taylor Erickson, Yeriel Estrada, James G Krueger, Stephanie M Rangel, Amy S Paller, Emma Guttman-Yassky
Background: While B-cells have historically been implicated in allergy development, a growing body of evidence supports their role in atopic dermatitis (AD). B-cell differentiation across ages in AD, and its relation to disease severity scores, has not been well defined.
Objective: To compare the frequency of B-cell subsets in blood of 0-5, 6-11, 12-17, and ≥18 years old patients with AD versus age-matched controls.
Methods: Flow cytometry was used to measure B-cell subset frequencies in the blood of 27 infants, 17 children, 11 adolescents, and 31 adults with moderate-to-severe AD and age-matched controls. IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometry panel were used to determine frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgEs) levels were measured using ImmunoCAP®.
Results: Adolescents with AD had lower frequencies of major B-cells subsets (p < .03). CD23 expression increased with age and was higher in AD compared to controls across all age groups (p < .04). In AD patients, multiple positive correlations were observed between IL-17-producing T-cells and B-cell subsets, most significantly non-switched memory (NSM) B-cells (r = .41, p = .0005). AD severity positively correlated with a list of B-cell subsets (p < .05). IL-9 levels gradually increased during childhood, reaching a peak in adolescence, paralleling allergen sensitization, particularly in severe AD. Principal component analysis of the aggregated environmental sIgE data showed that while controls across all ages tightly clustered together, adolescents with AD demonstrated distinct clustering patterns relative to controls.
Conclusions: Multiple correlations between B-cells and T-cells, as well as disease severity measures, suggest a complex interplay of immune pathways in AD. Unique B-cell signature during adolescence, with concurrent allergen sensitization and IL-9 surge, point to a potentially wider window of opportunity to implement interventions that may prevent the progression of the atopic march.
背景:虽然 B 细胞历来被认为与过敏症的发生有关,但越来越多的证据支持它们在特应性皮炎(AD)中的作用。特应性皮炎患者不同年龄段的 B 细胞分化及其与疾病严重程度评分的关系尚未得到很好的界定:比较0-5岁、6-11岁、12-17岁和≥18岁AD患者与年龄匹配的对照组血液中B细胞亚群的频率:方法:使用流式细胞术测量了27名婴儿、17名儿童、11名青少年和31名中重度AD成人患者及年龄匹配对照组血液中B细胞亚群的频率。采用 IgD/CD27 和 CD24/CD38 核心门控系统以及 11 色流式细胞仪面板来确定循环 B 细胞亚群的频率。使用ImmunoCAP®测量血清总IgE和过敏原特异性IgE(sIgEs)水平:结果:患有 AD 的青少年的主要 B 细胞亚群的频率较低(P<0.05):B细胞和T细胞之间的多重相关性以及疾病严重程度的测量结果表明,AD患者的免疫途径之间存在复杂的相互作用。青春期独特的B细胞特征,以及同时出现的过敏原致敏和IL-9激增,为实施干预措施提供了更广阔的机会窗口,可预防特应性疾病的发展。
{"title":"Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood.","authors":"Tali Czarnowicki, Eden David, Kazuhiko Yamamura, Joseph Han, Helen He, Ana B Pavel, Jacob Glickman, Taylor Erickson, Yeriel Estrada, James G Krueger, Stephanie M Rangel, Amy S Paller, Emma Guttman-Yassky","doi":"10.1111/all.16225","DOIUrl":"10.1111/all.16225","url":null,"abstract":"<p><strong>Background: </strong>While B-cells have historically been implicated in allergy development, a growing body of evidence supports their role in atopic dermatitis (AD). B-cell differentiation across ages in AD, and its relation to disease severity scores, has not been well defined.</p><p><strong>Objective: </strong>To compare the frequency of B-cell subsets in blood of 0-5, 6-11, 12-17, and ≥18 years old patients with AD versus age-matched controls.</p><p><strong>Methods: </strong>Flow cytometry was used to measure B-cell subset frequencies in the blood of 27 infants, 17 children, 11 adolescents, and 31 adults with moderate-to-severe AD and age-matched controls. IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometry panel were used to determine frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgEs) levels were measured using ImmunoCAP®.</p><p><strong>Results: </strong>Adolescents with AD had lower frequencies of major B-cells subsets (p < .03). CD23 expression increased with age and was higher in AD compared to controls across all age groups (p < .04). In AD patients, multiple positive correlations were observed between IL-17-producing T-cells and B-cell subsets, most significantly non-switched memory (NSM) B-cells (r = .41, p = .0005). AD severity positively correlated with a list of B-cell subsets (p < .05). IL-9 levels gradually increased during childhood, reaching a peak in adolescence, paralleling allergen sensitization, particularly in severe AD. Principal component analysis of the aggregated environmental sIgE data showed that while controls across all ages tightly clustered together, adolescents with AD demonstrated distinct clustering patterns relative to controls.</p><p><strong>Conclusions: </strong>Multiple correlations between B-cells and T-cells, as well as disease severity measures, suggest a complex interplay of immune pathways in AD. Unique B-cell signature during adolescence, with concurrent allergen sensitization and IL-9 surge, point to a potentially wider window of opportunity to implement interventions that may prevent the progression of the atopic march.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141602949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-06-12DOI: 10.1111/all.16187
Nieves Fernández-Gallego, Raquel Castillo-González, Lucía Moreno-Serna, Antonio J García-Cívico, Elisa Sánchez-Martínez, Celia López-Sanz, Ana Luiza Fontes, Lígia L Pimentel, Ana Gradillas, David Obeso, René Neuhaus, Marta Ramírez-Huesca, Ignacio Ruiz-Fernández, Emilio Nuñez-Borque, Yolanda R Carrasco, Borja Ibáñez, Pilar Martín, Carlos Blanco, Coral Barbas, Domingo Barber, Luis M Rodríguez-Alcalá, Alma Villaseñor, Vanesa Esteban, Francisco Sánchez-Madrid, Rodrigo Jiménez-Saiz
Background: Allergic diseases begin early in life and are often chronic, thus creating an inflammatory environment that may precede or exacerbate other pathologies. In this regard, allergy has been associated to metabolic disorders and with a higher risk of cardiovascular disease, but the underlying mechanisms remain incompletely understood.
Methods: We used a murine model of allergy and atherosclerosis, different diets and sensitization methods, and cell-depleting strategies to ascertain the contribution of acute and late phase inflammation to dyslipidemia. Untargeted lipidomic analyses were applied to define the lipid fingerprint of allergic inflammation at different phases of allergic pathology. Expression of genes related to lipid metabolism was assessed in liver and adipose tissue at different times post-allergen challenge. Also, changes in serum triglycerides (TGs) were evaluated in a group of 59 patients ≥14 days after the onset of an allergic reaction.
Results: We found that allergic inflammation induces a unique lipid signature that is characterized by increased serum TGs and changes in the expression of genes related to lipid metabolism in liver and adipose tissue. Alterations in blood TGs following an allergic reaction are independent of T-cell-driven late phase inflammation. On the contrary, the IgG-mediated alternative pathway of anaphylaxis is sufficient to induce a TG increase and a unique lipid profile. Lastly, we demonstrated an increase in serum TGs in 59 patients after undergoing an allergic reaction.
Conclusion: Overall, this study reveals that IgG-mediated allergic inflammation regulates lipid metabolism.
{"title":"Allergic inflammation triggers dyslipidemia via IgG signalling.","authors":"Nieves Fernández-Gallego, Raquel Castillo-González, Lucía Moreno-Serna, Antonio J García-Cívico, Elisa Sánchez-Martínez, Celia López-Sanz, Ana Luiza Fontes, Lígia L Pimentel, Ana Gradillas, David Obeso, René Neuhaus, Marta Ramírez-Huesca, Ignacio Ruiz-Fernández, Emilio Nuñez-Borque, Yolanda R Carrasco, Borja Ibáñez, Pilar Martín, Carlos Blanco, Coral Barbas, Domingo Barber, Luis M Rodríguez-Alcalá, Alma Villaseñor, Vanesa Esteban, Francisco Sánchez-Madrid, Rodrigo Jiménez-Saiz","doi":"10.1111/all.16187","DOIUrl":"10.1111/all.16187","url":null,"abstract":"<p><strong>Background: </strong>Allergic diseases begin early in life and are often chronic, thus creating an inflammatory environment that may precede or exacerbate other pathologies. In this regard, allergy has been associated to metabolic disorders and with a higher risk of cardiovascular disease, but the underlying mechanisms remain incompletely understood.</p><p><strong>Methods: </strong>We used a murine model of allergy and atherosclerosis, different diets and sensitization methods, and cell-depleting strategies to ascertain the contribution of acute and late phase inflammation to dyslipidemia. Untargeted lipidomic analyses were applied to define the lipid fingerprint of allergic inflammation at different phases of allergic pathology. Expression of genes related to lipid metabolism was assessed in liver and adipose tissue at different times post-allergen challenge. Also, changes in serum triglycerides (TGs) were evaluated in a group of 59 patients ≥14 days after the onset of an allergic reaction.</p><p><strong>Results: </strong>We found that allergic inflammation induces a unique lipid signature that is characterized by increased serum TGs and changes in the expression of genes related to lipid metabolism in liver and adipose tissue. Alterations in blood TGs following an allergic reaction are independent of T-cell-driven late phase inflammation. On the contrary, the IgG-mediated alternative pathway of anaphylaxis is sufficient to induce a TG increase and a unique lipid profile. Lastly, we demonstrated an increase in serum TGs in 59 patients after undergoing an allergic reaction.</p><p><strong>Conclusion: </strong>Overall, this study reveals that IgG-mediated allergic inflammation regulates lipid metabolism.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141304851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-07-28DOI: 10.1111/all.16255
Patricia Vanessa Heinl, Edith Graulich, Benno Weigmann, Andrea Wangorsch, Robert Ose, Iris Bellinghausen, Rahul Khatri, Verena K Raker, Stephan Scheurer, Stefan Vieths, Joachim Saloga, Kerstin Steinbrink
Background: Approximately 70% of individuals allergic to birch pollen (Bet v 1.01 [Bet]) develop a secondary food allergy (e.g., hazelnut: Cor a 1.04 [Cor]), due to allergen cross-reactivity. However, standard immunotherapy for type I allergies often does not improve the food allergy sufficiently. We analyzed the allergen-specific and cross-reactive suppressive capacity of primary human regulatory T cells (Treg) induced by autologous IL-10-modulated dendritic cells (IL-10 DC) in vitro and in vivo.
Methods: CD4+ T cells of patients with birch pollen and associated hazelnut allergies were differentiated into Bet-specific or non-specific induced Treg (iTreg). After Bet- or Cor-specific restimulation the phenotype, proliferation, and suppressive capacity of iTreg subsets were analyzed. iTreg function was further investigated in humanized mouse models of airway and intestinal allergy, generated by engraftment of peripheral blood mononuclear cells from allergic donors into immunodeficient animals.
Results: After IL-10 DC priming and allergen-specific restimulation (Bet or Cor), non-specific control iTreg remained anergic, whereas Bet-specific iTreg proliferated extensively and exhibited a regulatory phenotype (enhanced expression of CTLA-4, PD-1, TNFR2, IL-10). Accordingly, activated Bet-specific iTreg displayed a high capacity to suppress Bet- and Cor-induced responder Th2 cell responses in vitro, indicating induction of both allergen-specific (birch) and cross-reactive tolerance (hazelnut). In vivo, the beneficial effect of Bet-specific iTreg was verified in humanized mouse models of allergic airway and intestinal inflammation, resulting in reduced allergen-induced clinical symptoms, and immune responses.
Conclusion: Human IL-10 DC-induced iTreg facilitate allergen-specific and cross-reactive tolerance. Therefore, they are potential candidates for regulatory cell therapy in allergic and autoimmune diseases.
背景:大约 70% 对桦树花粉(Bet v 1.01 [Bet])过敏的人由于过敏原交叉反应而继发食物过敏(如榛子:Cor a 1.04 [Cor])。然而,针对 I 型过敏的标准免疫疗法往往不能充分改善食物过敏。我们分析了自体 IL-10 调控树突状细胞(IL-10 DC)在体外和体内诱导的原发性人类调节性 T 细胞(Treg)的过敏原特异性和交叉反应抑制能力:方法:将桦树花粉过敏和相关榛子过敏患者的 CD4+ T 细胞分化成 Bet 特异性或非特异性诱导 Treg(iTreg)。通过将过敏捐献者的外周血单核细胞移植到免疫缺陷动物体内,在气道和肠道过敏的人源化小鼠模型中进一步研究了 iTreg 的功能:结果:在IL-10直流电引和过敏原特异性再刺激(Bet或Cor)后,非特异性对照iTreg仍具有过敏性,而Bet特异性iTreg则广泛增殖并表现出调控表型(CTLA-4、PD-1、TNFR2和IL-10的表达增强)。因此,活化的 Bet 特异性 iTreg 在体外抑制 Bet 和 Cor 诱导的应答者 Th2 细胞反应的能力很强,这表明既能诱导过敏原特异性耐受(桦树),也能诱导交叉反应耐受(榛子)。在体内,Bet 特异性 iTreg 的有益作用在过敏性气道和肠道炎症的人源化小鼠模型中得到了验证,从而减少了过敏原诱导的临床症状和免疫反应:结论:人类 IL-10 DC 诱导的 iTreg 可促进过敏原特异性和交叉反应性耐受。结论:人类 IL-10 DC 诱导的 iTreg 可促进过敏原特异性和交叉反应耐受,因此是过敏性和自身免疫性疾病调节细胞疗法的潜在候选者。
{"title":"IL-10-modulated dendritic cells from birch pollen- and hazelnut-allergic patients facilitate Treg-mediated allergen-specific and cross-reactive tolerance.","authors":"Patricia Vanessa Heinl, Edith Graulich, Benno Weigmann, Andrea Wangorsch, Robert Ose, Iris Bellinghausen, Rahul Khatri, Verena K Raker, Stephan Scheurer, Stefan Vieths, Joachim Saloga, Kerstin Steinbrink","doi":"10.1111/all.16255","DOIUrl":"10.1111/all.16255","url":null,"abstract":"<p><strong>Background: </strong>Approximately 70% of individuals allergic to birch pollen (Bet v 1.01 [Bet]) develop a secondary food allergy (e.g., hazelnut: Cor a 1.04 [Cor]), due to allergen cross-reactivity. However, standard immunotherapy for type I allergies often does not improve the food allergy sufficiently. We analyzed the allergen-specific and cross-reactive suppressive capacity of primary human regulatory T cells (Treg) induced by autologous IL-10-modulated dendritic cells (IL-10 DC) in vitro and in vivo.</p><p><strong>Methods: </strong>CD4<sup>+</sup> T cells of patients with birch pollen and associated hazelnut allergies were differentiated into Bet-specific or non-specific induced Treg (iTreg). After Bet- or Cor-specific restimulation the phenotype, proliferation, and suppressive capacity of iTreg subsets were analyzed. iTreg function was further investigated in humanized mouse models of airway and intestinal allergy, generated by engraftment of peripheral blood mononuclear cells from allergic donors into immunodeficient animals.</p><p><strong>Results: </strong>After IL-10 DC priming and allergen-specific restimulation (Bet or Cor), non-specific control iTreg remained anergic, whereas Bet-specific iTreg proliferated extensively and exhibited a regulatory phenotype (enhanced expression of CTLA-4, PD-1, TNFR2, IL-10). Accordingly, activated Bet-specific iTreg displayed a high capacity to suppress Bet- and Cor-induced responder Th2 cell responses in vitro, indicating induction of both allergen-specific (birch) and cross-reactive tolerance (hazelnut). In vivo, the beneficial effect of Bet-specific iTreg was verified in humanized mouse models of allergic airway and intestinal inflammation, resulting in reduced allergen-induced clinical symptoms, and immune responses.</p><p><strong>Conclusion: </strong>Human IL-10 DC-induced iTreg facilitate allergen-specific and cross-reactive tolerance. Therefore, they are potential candidates for regulatory cell therapy in allergic and autoimmune diseases.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141786582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-08-21DOI: 10.1111/all.16265
Serena Yun-Chen Tsai, Jonathan M Gaffin, Elena B Hawryluk, Hana B Ruran, Lisa M Bartnikas, Michiko K Oyoshi, Lynda C Schneider, Wanda Phipatanakul, Kevin Sheng-Kai Ma
Background: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.
Methods: In this population-based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity-score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new-onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0-5 years, 6-11 years, and 12-17 years), sex, and race.
Results: A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new-onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59-0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52-0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63-0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51-0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39-0.70] and anxiety [RR, 0.57; 95% CI, 0.46-0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47-0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38-0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0-5 years) with AD.
Conclusions: Treatment with dupilumab compared to systemic agents resulted in reductions in AD-related comorbidities in pediatric patients.
{"title":"Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.","authors":"Serena Yun-Chen Tsai, Jonathan M Gaffin, Elena B Hawryluk, Hana B Ruran, Lisa M Bartnikas, Michiko K Oyoshi, Lynda C Schneider, Wanda Phipatanakul, Kevin Sheng-Kai Ma","doi":"10.1111/all.16265","DOIUrl":"10.1111/all.16265","url":null,"abstract":"<p><strong>Background: </strong>Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.</p><p><strong>Methods: </strong>In this population-based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity-score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new-onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0-5 years, 6-11 years, and 12-17 years), sex, and race.</p><p><strong>Results: </strong>A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new-onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59-0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52-0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63-0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51-0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39-0.70] and anxiety [RR, 0.57; 95% CI, 0.46-0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47-0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38-0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0-5 years) with AD.</p><p><strong>Conclusions: </strong>Treatment with dupilumab compared to systemic agents resulted in reductions in AD-related comorbidities in pediatric patients.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142007898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-05-15DOI: 10.1111/all.16155
Jian Tan, Camille Potier-Villette, Duan Ni, Maike Hoeckh, Jemma Taitz, Stephen J Simpson, Ralph Nanan, Laurence Macia
{"title":"Succinate induces a Th2 environment in the small intestine but does not exacerbate food allergy.","authors":"Jian Tan, Camille Potier-Villette, Duan Ni, Maike Hoeckh, Jemma Taitz, Stephen J Simpson, Ralph Nanan, Laurence Macia","doi":"10.1111/all.16155","DOIUrl":"10.1111/all.16155","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140920202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-05-10DOI: 10.1111/all.16157
Maral Ranjbar, Christiane E Whetstone, Ruth P Cusack, Dhuha Al-Sajee, Hafsa Omer, Nadia Alsaji, Terence Ho, MyLinh Duong, Patrick Mitchell, Imran Satia, Paul K Keith, Yanqing Xie, Jonathan MacLean, Doron D Sommer, Paul M O'Byrne, Roma Sehmi, Gail M Gauvreau
{"title":"Comparison of upper and lower airway expression of SARS-CoV-2 receptors in allergic asthma.","authors":"Maral Ranjbar, Christiane E Whetstone, Ruth P Cusack, Dhuha Al-Sajee, Hafsa Omer, Nadia Alsaji, Terence Ho, MyLinh Duong, Patrick Mitchell, Imran Satia, Paul K Keith, Yanqing Xie, Jonathan MacLean, Doron D Sommer, Paul M O'Byrne, Roma Sehmi, Gail M Gauvreau","doi":"10.1111/all.16157","DOIUrl":"10.1111/all.16157","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}